Top

Published in:

01-03-2017 | Laboratory Investigation

Functional analysis of KIF20A, a potential immunotherapeutic target for glioma

Authors: Katsuya Saito, Shigeki Ohta, Yutaka Kawakami, Kazunari Yoshida, Masahiro Toda

Published in: Journal of Neuro-Oncology | Issue 1/2017

Abstract

Kinesin family member 20A (KIF20A), an ideal cancer-testis antigen, was reported to be a promising immunotherapeutic target for pancreatic cancers. Clinical trials of KIF20A peptide vaccine immunotherapy have been conducted against pancreatic cancers. To demonstrate the efficacy of KIF20A as a candidate molecular target for gliomas, we analyzed the expression and function of KIF20A in gliomas. Western blot and quantitative PCR analyses showed that KIF20A expression in glioma cell lines and glioma tissues was high compared with that found in a normal brain. KIF20A immunostaining of glioma cells and glioma tissues demonstrated that KIF20A was involved in spindle formation and cytokinesis, and that KIF20A was highly expressed, especially in glioma cells undergoing mitosis. In silico analysis of a cancer microarray database revealed that KIF20A was highly expressed in gliomas depending on the pathological grade, and glioma patients with higher expression of KIF20A showed poorer prognosis. Down-regulating KIF20A reduced cell proliferation in glioma cells due to the failure of cytokinesis and generation of binucleated cells. Additionally, KIF20A inhibition induced significant apoptosis in SF126 glioma cells. Taken together, KIF20A is a tumor-associated antigen involved in the glioma cell growth and cell survival, suggesting that KIF20A is an oncoantigen of gliomas. Thus, KIF20A is a candidate novel immunotherapeutic target for gliomas.

Available only for authorised users

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996CrossRefPubMed

Imai K, Hirata S, Irie A, Senju S, Ikuta Y et al (2011) Identification of HLA-A2-restricted CTL epitopes of a novel tumour-associated antigen, KIF20A, overexpressed in pancreatic cancer. Br J Cancer 104:300–307CrossRefPubMed

Nakamura T, Furukawa Y, Nakagawa H, Tsunoda T, Ohigashi H et al (2004) Genome-wide cDNA microarray analysis of gene expression profiles in pancreatic cancers using populations of tumor cells and normal ductal epithelial cells selected for purity by laser microdissection. Oncogene 23:2385–2400CrossRefPubMed

Echard A, Jollivet F, Martinez O, Lacapere JJ, Rousselet A et al (1998) Interaction of a Golgi-associated kinesin-like protein with Rab6. Science 279:580–585CrossRefPubMed

Hirokawa N, Noda Y, Okada Y (1998) Kinesin and dynein superfamily proteins in organelle transport and cell division. Curr Opin Cell Biol 10:60–73CrossRefPubMed

Allan VJ, Schroer TA (1999) Membrane motors. Curr Opin Cell Biol 11:476–482CrossRefPubMed

Gasnereau I, Boissan M, Margall-Ducos G, Couchy G, Wendum D et al (2012) KIF20A mRNA and its product MKlp2 are increased during hepatocyte proliferation and hepatocarcinogenesis. Am J Pathol 180:131–140CrossRefPubMed

Yamashita J, Fukushima S, Jinnin M, Honda N, Makino K et al (2012) Kinesin family member 20 A is a novel melanoma-associated antigen. Acta Derm Venereol 92:593–597CrossRefPubMed

Phuphanich S, Wheeler CJ, Rudnick JD, Mazer M, Wang H et al (2012) Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunol Immunother 62:125–135CrossRefPubMedPubMedCentral

10.

Yu JS, Liu G, Ying H, Yong WH, Black KL et al (2004) Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 64:4973–4979CrossRefPubMed

11.

Asahara S, Takeda K, Yamao K, Maguchi H, Yamaue H (2013) Phase I/II clinical trial using HLA-A24-restricted peptide vaccine derived from KIF20A for patients with advanced pancreatic cancer. J Transl Med 11:291CrossRefPubMedPubMedCentral

12.

Taniuchi K, Nakagawa H, Nakamura T, Eguchi H, Ohigashi H et al (2005) Down-regulation of RAB6KIFL/KIF20A, a kinesin involved with membrane trafficking of discs large homologue 5, can attenuate growth of pancreatic cancer cell. Cancer Res 65:105–112PubMed

13.

Hill E, Clarke M, Barr FA (2000) The Rab6-binding kinesin, Rab6-KIFL, is required for cytokinesis. EMBO J 19:5711–5719CrossRefPubMedPubMedCentral

14.

McCollum D (2004) Cytokinesis: the central spindle takes center stage. Curr Biol 14:R953–R955CrossRefPubMed

15.

Gruneberg U, Neef R, Honda R, Nigg EA, Barr FA (2004) Relocation of Aurora B from centromeres to the central spindle at the metaphase to anaphase transition requires MKlp2. J Cell Biol 166:167–172CrossRefPubMedPubMedCentral

16.

Echard A (1998) Interaction of a Golgi-Associated Kinesin-Like Protein with Rab6. Science 279:580–585CrossRefPubMed

17.

Hirokawa N, Noda Y, Tanaka Y, Niwa S (2009) Kinesin superfamily motor proteins and intracellular transport. Nat Rev Mol Cell Biol 10:682–696CrossRefPubMed

18.

Jordens I, Marsman M, Kuijl C, Neefjes J (2005) Rab proteins, connecting transport and vesicle fusion. Traffic 6:1070–1077CrossRefPubMed

19.

Okuyama R, Aruga A, Hatori T, Takeda K, Yamamoto M (2013) Immunological responses to a multi-peptide vaccine targeting cancer-testis antigens and VEGFRs in advanced pancreatic cancer patients. Oncoimmunology 2:e27010CrossRefPubMedPubMedCentral

20.

Tomita Y, Yuno A, Tsukamoto H, Senju S, Kuroda Y et al (2013) Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumor. Clin Cancer Res 19:4508–4520CrossRefPubMed

21.

Eggert US, Mitchison TJ, Field CM (2006) Animal cytokinesis: from parts list to mechanisms. Annu Rev Biochem 75:543–566CrossRefPubMed

22.

Glotzer M (2005) The molecular requirements for cytokinesis. Science 307:1735–1739CrossRefPubMed

23.

Miki H, Setou M, Kaneshiro K, Hirokawa N (2001) All kinesin superfamily protein, KIF genes in mouse and human. Proc Natl Acad Sci USA 98:7004–7011CrossRefPubMedPubMedCentral

24.

Straight AF, Field CM (2000) Microtubules, membranes and cytokinesis. Curr Biol 10:R760–R770CrossRefPubMed

25.

Wheatley SP, Wang Y (1996) Midzone microtubule bundles are continuously required for cytokinesis in cultured epithelial cells. J Cell Biol 135:981–989CrossRefPubMed

26.

Yan GR, Zou FY, Dang BL, Zhang Y, Yu G et al (2012) Genistein-induced mitotic arrest of gastric cancer cells by downregulating KIF20A, a proteomics study. Proteomics 12:2391–2399CrossRefPubMed

27.

Yu Y, Feng YM (2010) The role of kinesin family proteins in tumorigenesis and progression: potential biomarkers and molecular targets for cancer therapy. Cancer 116:5150–5160CrossRefPubMed

28.

Adams RR, Carmena M, Earnshaw WC (2001) Chromosomal passengers and the (aurora) ABCs of mitosis. Trends Cell Biol 11:49–54CrossRefPubMed

29.

D’Avino PP, Savoian MS, Glover DM (2005) Cleavage furrow formation and ingression during animal cytokinesis: a microtubule legacy. J Cell Sci 118:1549–1558CrossRefPubMed

30.

Ainsztein AM, Kandels-Lewis SE, Mackay AM, Earnshaw WC (1998) INCENP centromere and spindle targeting: identification of essential conserved motifs and involvement of heterochromatin protein HP1. J Cell Biol 143:1763–1774CrossRefPubMedPubMedCentral

31.

Ruchaud S, Carmena M, Earnshaw WC (2007) Chromosomal passengers: conducting cell division. Nat Rev Mol Cell Biol 8:798–812CrossRefPubMed

32.

Buczkowicz P, Zarghooni M, Bartels U, Morrison A, Misuraca KL et al (2013) Aurora kinase B is a potential therapeutic target in pediatric diffuse intrinsic pontine glioma. Brain Pathol 23:244–253CrossRefPubMed

33.

Carvajal RD, Tse A, Schwartz GK (2006) Aurora kinases: new targets for cancer therapy. Clin Cancer Res 12:6869–6875CrossRefPubMed

34.

Portella G, Passaro C, Chieffi P (2011) Aurora B: a new prognostic marker and therapeutic target in cancer. Curr Med Chem 18:482–496CrossRefPubMed

35.

Yeung SC, Gully C, Lee MH (2008) Aurora-B kinase inhibitors for cancer chemotherapy. Mini Rev Med Chem 8:1514–1525CrossRefPubMed

36.

Zeng WF, Navaratne K, Prayson RA, Weil RJ (2007) Aurora B expression correlates with aggressive behaviour in glioblastoma multiforme. J Clin Pathol 60:218–221CrossRefPubMedPubMedCentral

37.

Jung Y, Joo KM, Seong DH, Choi YL, Kong DS et al (2012) Identification of prognostic biomarkers for glioblastomas using protein expression profiling. Int J Oncol 40:1122–1132PubMed

38.

Kajiwara Y, Yamasaki F, Hama S, Yahara K, Yoshioka H et al (2003) Expression of survivin in astrocytic tumors: correlation with malignant grade and prognosis. Cancer 97:1077–1083CrossRefPubMed

39.

Uematsu M, Ohsawa I, Aokage T, Nishimaki K, Matsumoto K et al (2005) Prognostic significance of the immunohistochemical index of survivin in glioma: a comparative study with the MIB-1 index. J Neurooncol 72:231–238CrossRefPubMed

40.

Zhen HN, Zhang X, Hu PZ, Yang TT, Fei Z et al (2005) Survivin expression and its relation with proliferation, apoptosis, and angiogenesis in brain gliomas. Cancer 104:2775–2783CrossRefPubMed

41.

Ngan CY, Yamamoto H, Takagi A, Fujie Y, Takemasa I et al (2008) Oxaliplatin induces mitotic catastrophe and apoptosis in esophageal cancer cells. Cancer Sci 99:129–139PubMed

42.

Vitale I, Galluzzi L, Castedo M, Kroemer G (2011) Mitotic catastrophe: a mechanism for avoiding genomic instability. Nat Rev Mol Cell Biol 12:385–392CrossRefPubMed

43.

Wonsey DR, Follettie MT (2005) Loss of the forkhead transcription factor FoxM1 causes centrosome amplification and mitotic catastrophe. Cancer Res 65:5181–5189CrossRefPubMed

44.

Kenney-Herbert EM, Ball SL, Al-Mayhani TM, Watts C (2011) Glioblastoma cell lines derived under serum-free conditions can be used as an in vitro model system to evaluate therapeutic response. Cancer Lett 305:50–57CrossRefPubMed

45.

Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q et al (2006) Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9:391–403CrossRefPubMed

46.

Vik-Mo EO, Sandberg C, Olstorn H, Varghese M, Brandal P et al (2010) Brain tumor stemcells maintain overall phenotype and tumorigenicity after in vitro culturing in serum-free conditions. Neuro Oncol 12:1220–1230PubMedPubMedCentral

Title: Functional analysis of KIF20A, a potential immunotherapeutic target for glioma
Authors: Katsuya Saito
Shigeki Ohta
Yutaka Kawakami
Kazunari Yoshida
Masahiro Toda
Publication date: 01-03-2017
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 1/2017
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-016-2360-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Functional analysis of KIF20A, a potential immunotherapeutic target for glioma

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2017

The clinical and financial impact of a pediatric surgical neuro-oncology clinical trial

Survival in pediatric medulloblastoma: a population-based observational study to improve prognostication

11C-Methionine positron emission tomography delineates non-contrast enhancing tumor regions at high risk for recurrence in pediatric high-grade glioma

The role of histone modifications and telomere alterations in the pathogenesis of diffuse gliomas in adults and children

The safety of resection for primary central nervous system lymphoma: a single institution retrospective analysis

A clinicopathologic study of extraventricular neurocytoma